NEW YORK (GenomeWeb) – The Korean Ministry of Food and Drug Safety has cleared Gencurix's GenesWell ddEGFR Mutation Test for clinical use as a companion diagnostic, the company said this week.

Gencurix's assay can be used to select which non-small cell lung cancer patients will respond to tyrosine kinase inhibitors. The test is run on Bio-Rad's droplet digital PCR-based platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.